Back to today’s briefing

Story perspectives

Revolutionary Gene-Editing Drug Trials Begin for Heart Disease

5/15/2025

28 6

Summary

Story summary

A groundbreaking gene-editing drug, Nexiguran Ziclumeran, is set to tackle transthyretin amyloid cardiomyopathy (ATTR-CM) in Singapore. Under the guidance of Prof Lin Weiqin, eight patients, including Mr. Chua Ah Hai, have joined the trial. If successful, this innovative treatment could transform adult cardiology and hit the market by the end of the decade.

1 of 1

Story summary

A groundbreaking gene-editing drug, Nexiguran Ziclumeran, is set to tackle transthyretin amyloid cardiomyopathy (ATTR-CM) in Singapore. Under the guidance of Prof Lin Weiqin, eight patients, including Mr. Chua Ah Hai, have joined the trial. If successful, this innovative treatment could transform adult cardiology and hit the market by the end of the decade.